STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,363,287)	$ (11,512,492)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	632,915	663,988
Share based payments for services	232,847	751,651
Equity based compensation	1,380,500	2,113,433
Common stock contributed to 401(k) plan	151,308	161,571
Ergomed stock issuance	1,310,400	0
Loss on retired equipment	1,187	248
Gain on derivative instruments	(11,007,215)	(14,013,726)
Amortization of debt discount	917,692	0
Capitalized lease interest	200,902	227,773
(Increase)/decrease in assets:
Receivables	(129,307)	(1,960)
Prepaid expenses	151,909	15,999
Inventory used for R&D and manufacturing	336,120	393,197
Deposits	154,995	145,005
Increase/(decrease) in liabilities:
Accounts payable	5,420,816	(2,389,931)
Accrued expenses	558,026	290,097
Deferred revenue	0	(1,639)
Due to employees	256,303	72,397
Deferred rent liability	1,995	1,896
Net cash used in operating activities	(13,791,894)	(23,082,493)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(10,525)	(31,405)
Expenditures for patent costs	(6,477)	(2,819)
Net cash used in investing activities	(17,002)	(34,224)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	10,519,306	21,420,301
Payment on related party loan	0	(1,104,057)
Proceeds from notes payable	2,745,000	0
Payments on obligations under capital lease	(3,968)	(8,213)
Net cash provided by financing activities	13,260,338	20,308,031
NET DECREASE IN CASH AND CASH EQUIVALENTS	(548,558)	(2,808,686)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	2,917,996	5,726,682
CASH AND CASH EQUIVALENTS, END OF YEAR	2,369,438	2,917,996
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services	(305,341)	305,341
Conversion of notes payable to common stock	450,700	0
Lease payments included in accounts payable at year end	1,890	815
Fair value of warrant liabilities on the date of issuance reclassed to liabilities	(4,665,683)	(8,722,073)
Financing costs included in accounts payable at year end	35,605	46,605
Prepaid amount under consulting services paid with issuance of common stock	(3,339)	18,021
Conversion of accrued salaries and fees to notes payable	275,000	0
Cash paid for interest expense	$ 1,888,612	$ 1,900,567